PULMATRIX, INC (NASDAQ:PULM) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On July 8, 2020, Pulmatrix, Inc. (the “Company”) issued a press release announcing that Sensory Cloud, Inc., which licensed the rights to the Company’s NasoCalm proprietary formulations (PUR003 and PUR006), plans to commence commercial sales of FEND in September 2020. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| 99.1 | Press release dated July 8, 2020 |
Pulmatrix, Inc. Exhibit
EX-99.1 2 ex99-1.htm Exhibit 99.1 Pulmatrix Announces Progress by Sensory Cloud Toward Commercial Launch of FEND in Fall 2020,…
To view the full exhibit click here
About PULMATRIX, INC (NASDAQ:PULM)
Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.